MDBH

Business Context and Reporting Period

Company: MDB Capital Holdings, LLC (MDBH)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Business Overview: MDB is a holding company operating through two primary segments: (1) Broker Dealer & Intellectual Property Services (Public Ventures and PatentVest) and (2) Technology Development (MDB Minnesota One "M1" and equity interest in eXoZymes). Notably, eXoZymes was deconsolidated in November 2024 following its IPO and is now accounted for as an equity method investment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Improvement: The company shifted from an operating loss of $(660,389) in Q1 2024 to operating income of $828,098 in Q1 2025. This was driven primarily by $2.14 million in fee income from investment banking activities and self-clearing operations, partially offset by an unrealized loss of $1.46 million on investment securities.
• Reduced Net Loss: Net loss decreased by approximately 13.2% year-over-year. This improvement is largely attributed to the deconsolidation of eXoZymes, which removed significant R&D expenses and operating costs from the consolidated statements.
• Equity Method Investment: The company recorded an $872,518 equity in loss from its 47% stake in eXoZymes, which was not present in the prior year's consolidated results.
• Expense Reductions: Total operating costs decreased by 7.5% to $6.74 million. Compensation expenses dropped by 11.4% due to the deconsolidation of eXoZymes and forfeiture of restricted stock units. R&D costs dropped 100% as eXoZymes is no longer consolidated.
• Liquidity: Working capital decreased by $7.1 million to $20.2 million, primarily due to cash utilization for operations and a reduction in segregated cash and clearing deposits.

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management attributes the improved operating results to successful investment banking deals in February 2025 and the structural change of deconsolidating eXoZymes. The broker-dealer segment is expanding self-clearing operations, driving higher fee income but also higher clearing and IT costs.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses in internal control over financial reporting. Remediation efforts are ongoing, including redesigning financial reporting processes.
• Risk Factors:
  • Regulatory & Trade: Potential adverse effects from new U.S. tariffs, trade policy changes, and restrictions on research grants could impact partner companies and capital raising.
  • Technology Development: High risk associated with the commercial viability of M1's pharmaceutical platform and eXoZymes' technology.
  • Net Capital Requirements: Public Ventures must maintain minimum net capital; while currently compliant ($10.2M net capital vs. $250k minimum), this requirement may limit dividend distributions.
• Unusual Items:
  • Warrant Receipts: The company received warrants valued at $990,426 as part of an investment banking deal, recorded as a non-cash adjustment.
  • Stock-Based Compensation: Significant non-cash expense of $3.51 million recognized in Q1 2025.

Investor Verification Checklist

• Internal Control Remediation: Verify the timeline and progress of remediation for the material weaknesses in internal controls over financial reporting.
• eXoZymes Performance: Monitor the financial performance of eXoZymes (now an equity method investment) to assess the sustainability of the $872k quarterly loss impact.
• Broker-Dealer Growth: Confirm the sustainability of the $2.14M fee income and whether self-clearing operations can consistently offset unrealized investment losses.
• Cash Burn Rate: Assess the runway given the $1.26M cash burn from operations and the lack of revenue in the Technology Development segment (M1).
• Regulatory Compliance: Review Public Ventures' net capital ratios and compliance with SEC Rule 15c3-1 to ensure no restrictions on capital movements.